https://www.thebodypro.com/article/top-weight-gain-hiv-antiretrovirals
Adverse Events, Comorbidities, and HIVFeatures

Weight Gain and HIV Antiretrovirals: Lipodystrophy for the Integrase Era

#1 in TheBodyPro's Top 10 HIV Clinical Developments of 2019

Weight Gain and HIV Antiretrovirals photo illustration
Photo illustration: Remedy Health Media; Background and paper tear: iStock

    ADVANCE and NAMSCAL results at IAS 2019: 10th IAS Conference on HIV Science. (2019). "Progressive rises in weight and clinical obesity for TAF/FTC/DTG and TDF/FTC/DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials." programme.ias2019.org/Abstract/Abstract/4772

    Published ADVANCE results: New England Journal of Medicine. (2019). "Dolutegravir plus two different prodrugs of tenofovir to treat HIV." nejm.org/doi/full/10.1056/NEJMoa1902824

    ADVANCE 96-week results: 17th European AIDS Conference. (2019). "The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC+DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV." professionalabstracts.com/eacs2019/iplanner/#/presentation/243

    German INSTI study: 17th European AIDS Conference. (2019). "Hepatic steatosis in HIV monoinfected individuals: which impact has baseline BMI and treatment with integrase inhibitors?" professionalabstracts.com/eacs2019/iplanner/#/presentation/169

    NA-ACCORD INSTI data: IDWeek 2019. (2019). "The effect of initiating integrase inhibitor-based vs. non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy on progression to diabetes among North American persons in HIV care." eventscribe.com/2019/IDWeek/fsPopup.asp?Mode=presInfo&PresentationID=635008

    Bictegravir and dolutegravir eight-study analysis: Clinical Infectious Diseases. (2019). "Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Clinical Trials." doi.org/10.1093/cid/ciz999

    Doravarine 96-week results: 17th European AIDS Conference. (2019). "Effect of doravirine on body weight and body mass index in treatment naive adults with HIV-1." professionalabstracts.com/eacs2019/iplanner/#/presentation/245

    David Alain Wohl, M.D.

    David Alain Wohl, M.D.

    David Alain Wohl, M.D., is a professor at the University of North Carolina, site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AETC, and co-director of HIV services for the NC state prison system.